Johnson & Johnson is trading 3.1% up at $235.13 as investors rotate into defensive healthcare stocks amid a broader market decline.
- The gain comes despite sharp losses in the S&P 500 and Nasdaq, signaling a flight-to-quality move as risk appetite fades.
- Investors are favoring dividend-paying names as interest rates remain elevated and macro uncertainty persists.
- The price action appears driven by macro-economic factors rather than any specific company news or catalysts.